A16z makes first 'DeSci' investment in decentralized biobank platform AminoChain

Quick Take

  • Andreessen Horowitz’s first DeSci investment is AminoChain, which has raised $7 million is pre-seed and seed financing.
  • AminoChain is building a “decentralized biobank” and Layer 2 network, which will connect enterprise medical institutions looking to share medical data.

Major venture capital firm Andreessen Horowitz has invested in its first "DeSci" (as in "decentralized science") project — AminoChain, according to a16z General Partner Arriana Simpson on X. A16z led the $5 million seed round announced on Wednesday. 

The project is looking to bring “ownership, transparency, and consent” into the field of medical data collection using blockchain technology. AminoChain is building a “decentralized biobank” and Layer 2 network that will connect enterprise medical institutions looking to share medical data while preserving patient privacy, Simpson said. 

According to AminoChain’s website, medical institutions can install “Amino Node” software and integrate it with its existing tech stack. “While data stays self-custodial on the given institutions' servers, the Node software harmonizes and standardizes the data into a common format, making it interoperable with a network of collaborators,” the startup said. 

“The Node software thereby sources data from all providers and brings credible neutrality to the network; from this basis, developers can source data from a multitude of medical bodies and build any number of patient-centric applications,” AminoChain continued. 

Decentralized science, or DeSci, refers to the use of blockchain to make various aspects of scientific research and collaboration more open, incentivized and community-driven. 

The first application that will be built on AminoChain will be a peer-to-peer marketplace for “bio-samples” called the Specimen Center, which will house an inventory of research samples of human tissue potentially useful for scientific research.

“With Specimen Center, biobanks can now give permission for researchers and collaborators to query their sample collections, and they can equally query for research assets available to them. Between institutions, users can streamline licensing agreements, track sample and data use, and maintain full provenance of biosamples across an interoperable network of biobanks,” the company said. 

AminoChain previously raised $2 million in pre-seed financing, bringing its total raised to date to $7 million.


Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2024 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

About Author

Daniel Kuhn is a Senior Journalist and Editor at The Block, where he covers the crypto industry with a particular focus on tech. He previously served as deputy managing editor of opinion/features at CoinDesk. He first appeared in print in Financial Planning, a trade publication magazine. Before journalism, he studied philosophy as an undergrad, English literature in graduate school and business and economic reporting at an NYU professional program. You can connect with him on Twitter and Telegram @danielgkuhn or find him on Urbit as ~dorrys-lonreb.

Editor

To contact the editor of this story:
Lawrence Lewitinn at
[email protected]